These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22650422)

  • 1. Therapeutic strategies for the prevention and treatment of cytomegalovirus infection.
    Sellar RS; Peggs KS
    Expert Opin Biol Ther; 2012 Sep; 12(9):1161-72. PubMed ID: 22650422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.
    Sellar RS; Peggs KS
    Expert Opin Biol Ther; 2014 Aug; 14(8):1121-6. PubMed ID: 24762099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.
    Peggs KS; Verfuerth S; Pizzey A; Chow SL; Thomson K; Mackinnon S
    Clin Infect Dis; 2009 Dec; 49(12):1851-60. PubMed ID: 19911966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.
    Mackinnon S; Thomson K; Verfuerth S; Peggs K; Lowdell M
    Blood Cells Mol Dis; 2008; 40(1):63-7. PubMed ID: 17869548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive T cell immunotherapy for cytomegalovirus.
    Peggs KS
    Expert Opin Biol Ther; 2009 Jun; 9(6):725-36. PubMed ID: 19456207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation.
    Peggs KS; Thomson K; Samuel E; Dyer G; Armoogum J; Chakraverty R; Pang K; Mackinnon S; Lowdell MW
    Clin Infect Dis; 2011 Jan; 52(1):49-57. PubMed ID: 21148519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
    Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
    Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
    Peggs KS; Mackinnon S
    Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment.
    Benmarzouk-Hidalgo OJ; Cisneros JM; Cordero E; Martín-Peña A; Sanchez B; Martin-Gandul C; Gentil MA; Gomez-Bravo MA; Lage E; Perez-Romero P
    Transplantation; 2011 Apr; 91(8):927-33. PubMed ID: 21358366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients.
    Amini L; Vollmer T; Wendering DJ; Jurisch A; Landwehr-Kenzel S; Otto NM; Jürchott K; Volk HD; Reinke P; Schmueck-Henneresse M
    Front Immunol; 2019; 10():1148. PubMed ID: 31191530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.
    Boeckh M; Murphy WJ; Peggs KS
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):24-9. PubMed ID: 25452035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials with CMV-specific T cells.
    Peggs KS; Mackinnon S
    Cytotherapy; 2002; 4(1):21-8. PubMed ID: 11953038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies.
    Muñoz-Cobo B; Solano C; Costa E; Bravo D; Clari MÁ; Benet I; Remigia MJ; Montoro J; Navarro D
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1602-11. PubMed ID: 21871245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.
    Le Page AK; Jager MM; Iwasenko JM; Scott GM; Alain S; Rawlinson WD
    Clin Infect Dis; 2013 Apr; 56(7):1018-29. PubMed ID: 23243176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Maffini E; Busca A; Costa C; Giaccone L; Cerrano M; Curtoni A; Cavallo R; Bruno B
    Expert Rev Hematol; 2019 Nov; 12(11):937-945. PubMed ID: 31423858
    [No Abstract]   [Full Text] [Related]  

  • 18. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
    Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
    Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for multidrug-resistant cytomegalovirus disease.
    Stuehler C; Stüssi G; Halter J; Nowakowska J; Schibli A; Battegay M; Dirks J; Passweg J; Heim D; Rovo A; Kalberer C; Bucher C; Weisser M; Dumoulin A; Hirsch HH; Khanna N
    Transpl Infect Dis; 2015 Oct; 17(5):751-5. PubMed ID: 26432076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
    Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
    J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.